Beta blockade in diabetic heart failure

Heart Failure Clinics

Volumn 2, Issue 1, 2006, Pages 89-99

  Lukas, Mary Ann ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; PLACEBO; PROPRANOLOL;

ADRENERGIC SYSTEM; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; META ANALYSIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; INSULIN RESISTANCE; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 33644881654     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.11.005     Document Type: Review

References (64)

1. E.J. Eichhorn, and M.R. Bristow Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure Circulation 94 1996 2285 2296
2. M.R. Bristow Mechanism of action of beta-blocking agents in heart failure Am J Cardiol 80 1997 26L 40L
3. M. Packer Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice Prog Cardiovasc Dis 41 1998 39 52
4. G.S. Francis, S.R. Goldsmith, and T.B. Levine The neurohumoral axis in congestive heart failure Ann Intern Med 101 1984 370 377
5. J.N. Cohn, T.B. Levine, and M.T. Olivari Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 1984 819 823
6. G.E. Billman, L.C. Castillo, and J. Hensley Beta 2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta 2-adrenergic stimulation in animals susceptible to sudden death Circulation 96 1997 1914 1922
7. V. Dzau, and E. Braunwald Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement Am Heart J 121 1991 1244 1263
8. T.D. Giles, and G.E. Sander Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations Cardiol Clin 22 2004 553 568
9. A.D. Baron The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide Diabetes 45 Suppl 1 1996 S105 S109
10. B.M. Egan Insulin resistance and the sympathetic nervous system Curr Hypertens Rep 5 2003 247 254
11. M. Esler, and D. Kaye Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure Journal of the Autonomic Nervous System 72 1998 210 219
12. H. Taegtmeyer, P. McNulty, and M.E. Young Adaptation and maladaptation of the heart in diabetes: part I: general concepts Circulation 105 2002 1727 1733
13. K. Malmberg, L. Ryden, and A. Hamsten Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Diabetes Insulin-Glucose in Acute Myocardial Infarction (DIGAMI) Study Group Eur Heart J 17 1996 1337 1344
14. W.Y. Tse, and M. Kendall Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 11 1994 137 144
15. D.S. Bell Use of beta blockers in the patient with diabetes Endocrinologist 13 2003 116 123
16. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
17. K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study Group BMJ 314 1997 1512 1515
18. M. Frohlich, A. Imhof, and G. Berg Association between C-reactive protein and features of the metabolic syndrome: a population-based study Diabetes Care 23 2000 1835 1839
19. N.P. Jenkins, B.G. Keevil, and I.V. Hutchinson Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease Am J Med 112 2002 269 274
20. S. Jacob, K. Rett, and M. Wicklmayr Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study J Hypertens 14 1996 489 494
21. S. Jacob, K. Rett, and E.J. Henriksen Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 11 1998 1258 1265
22. S. Jacob, B. Balletshofer, and E.J. Henriksen Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers Blood Press 8 1999 261 268
23. A.M. Sharma, T. Pischon, and S. Hardt Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis Hypertension 37 2001 250 254
24. D.H. Roberts, Y. Tsao, and G.A. McLoughlin Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication Lancet 2 1987 650 653
25. D.A. Popp, T.F. Tse, and S.D. Shah Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus Diabetes Care 7 1984 243 247
26. D. Kerr, I.A. MacDonald, and S.R. Heller Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects Br J Clin Pharmacol 29 1990 685 693
27. U. Hauf-Zachariou, L. Widmann, and B. Zulsdorf A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia Eur J Clin Pharmacol 45 1993 95 100
28. D. Giugliano, R. Acampora, and R. Marfella Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial Ann Intern Med 126 1997 955 959
29. G.L. Bakris, V. Fonseca, and R.E. Katholi Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial JAMA 292 2004 2227 2236
30. J. Refsgaard, C. Thomsen, and F. Andreasen Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure Eur J Heart Fail 4 2002 445 453
31. S. Ferrua, M. Bobbio, and E. Catalano Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail 11 2005 590 594
32. S.A. Hunt, W.T. Abraham, and M.H. Chin ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) Circulation 112 2005 e154 e235
33. Heart Failure Society of America HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches Pharmacotherapy 20 2000 495 522
34. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
35. CIBIS-II Investigators The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
36. MERIT-HF Investigators Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
37. M. Packer, A.J.S. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
38. Australia/New Zealand Heart Failure Research Collaborative Group Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease Lancet 349 1997 375 380
39. E. Erdmann, P. Lechat, and P. Verkenne Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure Eur J Heart Fail 3 2001 469 479
40. H. Wedel, D. DeMets, and P. Deedwania Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial Am Heart J 142 2001 502 511
41. Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
42. M. Domanski, H. Krause-Steinrauf, and P. Deedwania The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial J Am Coll Cardiol 42 2003 914 922
43. H. Krum, E.B. Roecker, and P. Mohacsi Efficacy and safety of initiating carvedilol in patients with severe chronic heart failure: results of COPERNICUS study. Presented at American Heart Association 75th Scientific Sessions. Chicago, Illinois, November 17-20, 2002 Circulation 106 2002 II612
44. G.C. Fonarow The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes Rev Cardiovasc Med 3 Suppl 3 2002 S2 S10
45. P. Mohacsi, M.B. Fowler, and H. Krum Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. Presented at the American Heart Association 74th Annual Scientific Sessions [abstract no. 3551]. Anaheim, California, November 14, 2001 Circulation 104 Suppl II 2001 II754
46. M.R. Bristow Effect of carvedilol on LV function and mortality in diabetic vs non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Presented at the American Heart Association 69th Scientific Sessions. New Orleans, Louisiana, November 10-13, 1996 Circulation 84 1996 I644
47. M.R. Bristow, E.M. Gilbert, and W.T. Abraham Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators Circulation 94 1996 2807 2816
48. P.A. Poole-Wilson, K. Swedberg, and J.G. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
49. Investigators CAPRICORN Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
50. Data on file. Philadelphia: GlaxoSmithKline
51. M.D. Flather, M.C. Shibata, and A.J. Coats Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
52. M. Bobbio, S. Ferrua, and C. Opasich Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers J Card Fail 9 2003 192 202
53. S.J. Haas, T. Vos, and R.E. Gilbert Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials Am Heart J 146 2003 848 853
54. P.G. Shekelle, M.W. Rich, and S.C. Morton Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials J Am Coll Cardiol 41 2003 1529 1538
55. P.C. Deedwania, T.D. Giles, and M. Klibaner Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF Am Heart J 149 2005 159 167
56. E.M. Gilbert, W.T. Abraham, and S. Olsen Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart Circulation 94 1996 2817 2825
57. T. Yoshikawa, J.D. Port, and K. Asano Cardiac adrenergic receptor effects of carvedilol Eur Heart J 17 Suppl B 1996 8 16
58. U.D. Dincer, K.R. Bidasee, and S. Guner The effect of diabetes on expression of beta1-, beta2-, and beta3- adrenoreceptors in rat hearts Diabetes 50 2001 455 461
59. H. Krum Tolerability of carvedilol in heart failure: clinical trials experience Am J Cardiol 93 2004 58 63
60. H. Krum, D. Ninio, and P. MacDonald Baseline predictors of tolerability to carvedilol in patients with chronic heart failure Heart 84 2000 615 619
61. H. Krum, J. Hill, and F. Fruhwald Tolerability of beta-blockers in elderly patients with chronic heart failure: The COLA II study Eur J Heart Fail 2005
62. S. Nodari, M. Metra, and C.A. Dei Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus Eur J Heart Fail 5 2003 803 809
63. C.J. Pepine Potential role of angiotensin-converting enzyme inhibition in myocardial ischemia and current clinical trials Clin Cardiol 20 1997 II58 II64
64. J.K. Edwin, and J.C. Garrison Renin and angiotensin J.G. Hardman L.E. Limbird P.B. Molinoff Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th edition 1996 McGraw-Hill New York